title: How do we treat people with dementia in Croatia.
abstract: The current clinical view on pharmacological treatment and the Croatian reality regarding approved antidementia drugs is presented. Dementia is a syndrome of high incidence and Alzheimer's disease is the most common cause of dementia. New data show that dementia prevalence will nearly double every 20 years, and we believe that current estimated number of persons with dementia (PWD) for Croatia is more than 80,000. The standard treatment with antidementia drugs is unavailable in Croatia, for the majority of PWD, because antidementia drugs are not on the reimbursement list, although Croatian algorithm for psychopharmacological treatment and Alzheimer Disease Societies Croatia recommend early and adequate treatment. Alzheimer's dementia is becoming a world's health priority in 21st century, so we strongly believe that antidementia drugs should be reimbursed in Croatia.
authors.affiliation: Psychiatric Hospital Vrapce, HR-10090 Zagreb, Croatia. ninoslav.mimica@bolnica-vrapce.hr
authors.forename: Ninoslav
authors.initials: N
authors.lastname: Mimica
authors.forename: Paola
authors.initials: P
authors.lastname: Presecki
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000453:epidemiology; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D017523:Croatia; D003431:Cross-Cultural Comparison; D003430:Cross-Sectional Studies; D000077265:Donepezil; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D008559:Memantine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D009313:National Health Programs; D018697:Nootropic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D048448:Phenylcarbamates / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D012051:Reimbursement Mechanisms; D000068836:Rivastigmine
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D000077265:Donepezil; D000068836:Rivastigmine; D008559:Memantine